Treatment of small intestine bacterial overgrowth and related symptoms by rifaximin

Chemotherapy

Volumn 51, Issue SUPPL. 1, 2005, Pages 103-109

  Di Stefano, Michele ^a   Corazza, Gino Roberto ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Nonabsorbable antibiotics; Rifaximin; Small intestine bacterial overgrowth; Therapy

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CHLORAMPHENICOL; CISAPRIDE; COTRIMOXAZOLE; LINCOMYCIN; METRONIDAZOLE; NORFLOXACIN; OCTREOTIDE; PROBIOTIC AGENT; RIFAXIMIN; TETRACYCLINE;

ANTIBIOTIC THERAPY; BACTERIAL OVERGROWTH; BACTERIAL STRAIN; BACTERIUM COLONY; BACTERIUM CONTAMINATION; BLIND LOOP SYNDROME; CARDIOTOXICITY; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DRUG EFFICACY; HUMAN; INTESTINE DIVERTICULOSIS; INTESTINE FISTULA; INTESTINE OBSTRUCTION; MALABSORPTION; METEORISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RELAPSE; REVIEW; SMALL INTESTINE DISEASE;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CLINICAL TRIALS; DIETARY SUPPLEMENTS; GASTROINTESTINAL AGENTS; HUMANS; INTESTINAL ABSORPTION; INTESTINAL DISEASES; INTESTINE, SMALL; RIFAMYCINS;

EID: 18644368910     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081996     Document Type: Review

References (46)

1. Donaldson RM Jr: Normal bacterial populations of the intestine and their relation to intestinal function. N Engl J Med 1964;270:938-945.
2. Saltzman JR, Kowdley KV, Pedrosa MC, Sepe T, Golner B, Perrone G, Russell RM: Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. Gastroenterology 1994;106:615-623.
3. King CE, Toskes PP: Small intestine bacterial overgrowth. Gastroenterology 1979;76:1035-1055.
4. Jones EA, Craigie A, Tavill AS, Franglen G, Rosenoer VM: Protein metabolism in the intestinal stagnant loop syndrome. Gut 1968;9:466-469.
5. Rutgeerts L, Mainguet P, Tytgat G, Eggermont E: Enterokinase in contaminated small-bowel syndrome. Digestion 1974;10:249-254.
6. Su J, Smith MB, Rerknimitr R, Morrow D: Small intestine bacterial overgrowth presenting as protein-losing enteropathy. Dig Dis Sci 1998;43:679-681.
7. 12 by the sediment of jejunal contents in patients with blind loop syndrome. Scand J Gastroenterol 1975;10:305-309.
8. 12 analogues in patients with small bowel bacterial overgrowth. Ann Intern Med 1977;87:546-551.
9. Di Stefano M, Veneto G, Malservisi S, Corazza GR: Small bowel bacterial overgrowth and metabolic osteopathy. Dig Dis Sci 2001;46:1077-1082.
10. Schiffer LM, Faloon WW, Chodos RB: Malabsorption syndrome associated with intestinal diverticulosis. Gastroenterology 1962;42:63-68.
11. Ament ME, Shimoda SS, Saunders DR, Rubin CE: Pathogenesis of steatorrhea in three cases of small intestinal stasis syndrome. Gastroenterology 1972;63:728-747.
12. Strocchi A, Levitt MD: Intestinal gas; in Sleisenger MH, Fordtran JS (eds): Gastrointestinal Disease. Philadelphia, Saunders, 1993, pp 1035-1042.
13. Riepe S, Goldstein J, Alpers DH: Effect of secreted Bacteroides proteases on human intestinal brush border hydrolases. J Clin Invest 1980;66:314-322.
14. Corazza GR, Menozzi MG, Strocchi A, Rasciti L, Vaira D, Lecchini R, Avanzini P, Chezzi C, Gasbarrini G: The diagnosis of small bowel bacterial overgrowth. Gastroenterology 1990;98:302-309.
15. Camilleri M, Malagelada JR, Abell TL, Brown ML, Hench V, Zinsmeister AR: Effect of six weeks of treatment with cisapride in gastroparesis with intestinal pseudoobstruction. Gastroenterology 1989;96:704-712.
16. Kaye SA, Lim SG, Taylor M, Patel S, Gillespie S, Black CM: Small bowel bacterial overgrowth in systemic sclerosis: Detection using direct and indirect methods and treatment outcome. Br J Rheumatol 1995;34:265-269.
17. Soudah HC, Hasler WL, Owyang C: Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 1991;325:1461-1467.
18. Nieuwenhuijs VB, van Duijvenbode-Beumer H, Verheen A, Visser MR, Vrhoef J, Gooszen HG, Akkermans LMA: The effects of ABT-229 and octreotide on interdigestive small bowel motility, bacterial overgrowth and bacterial translocation in rats. Eur J Clin Invest 1999;29:33-40.
19. Banwell JG, Kistel LA, Giannella RA, Weber FL, Lieber A, Powell DE: Small intestine bacterial overgrowth syndrome. Gastroenterology 1981;80:834-845.
20. Sherwood WC, Goldstein F, Haurani FI, et al: Studies of the small intestinal bacterial flora and of intestinal absorption in pernicious anemia. Am J Dig Dis 1964;9:416-425.
21. Kahn IJ, Jeffries GH, Sleisenger MH: Malabsorption in intestinal scleroderma: Correction by antibiotics. N Engl J Med 1966;274:1339-1344.
22. Goldstein F, Wirts CW, Kramer S: The relationship of afferent loop stasis and bacterial flora to the production of postgastrectomy steatorrhea. Gastroenterology 1961;40:47-54.
23. Bjorneklett A, Fausa O, Midtvedt T: Bacterial overgrowth in jejunal and ileal disease. Scand J Gastroenterol 1983;18:289-298.
24. Bjorneklett A, Hoverstad T, Hovig T: Bacterial overgrowth. Scand J Gastroenterol 1985;109: 123-132.
25. Toskes PP, Kumar A: Enteric bacterial flora and bacterial overgrowth syndrome; in Feldman M, Sleisenger MH, Scharschmidt BF (eds): Sleisenger & Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. Philadelphia, WB Saunders, 1998, pp 1523-1535.
26. Goldstein F, Wirts CW, Kowlessar OD: Diabetic diarrhea and steatorrhea. Ann Intern Med 1970;72:215-218.
27. Donaldson RM: Small bowel bacterial overgrowth. Adv Intern Med 1970;16:191-212.
28. Gorbach SL, Tabaqchali S: Bacteria, bile and the small bowel. Gut 1969;10:963-972.
29. Joiner KA, Gorbach SL: Antimicrobial therapy of digestive diseases. Clin Gastroenterol 1979;8:3-35.
30. Elsborg L: Malabsorption in small intestinal diverticulosis treated with a low dosage sulphonamide-trimethoprim. Dan Med Bull 1977;24:33-35.
31. Tabaqchali S: The pathophysiological role of small intestinal bacterial flora. Scand J Gastroenterol Suppl 1970;6:139-163.
32. Bouhnik Y, Alain S, Attar A, Flourie B, Raskine L, Sanson-Le Pors MJ, Rambaud JC: Bac-terial population contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am J Gastroenterol 1999;94:1327-1331.
33. Vinci M, Gatto A, Gilgio A, et al: Double-blind clinical trial on infectious diarrhoea therapy: Rifaximin versus placebo. Curr Ther Res 1984;36:92-99.
34. Lamanna A, Orsi A: In vitro activity of rifaximin and rifampicin against some anaerobic bacteria. Chemioterapia 1984;6:365-367.
35. DeLeo C, Eftimiadi C, Schito GC: Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res 1986;12:979-981.
36. Alvisi V, D'Ambrosi A, Onofri W, Castellani M: Treatment of secretory diarrhoeas. A double-blind trial of the effectiveness of rifaximin (L/105) and neomycin. Clin Trials J 1984;21:215-223.
37. Palermo G, Di Gregorio P, Coffa G: Effectiveness of the L 105 compound in the treatment of acute diarrhoeal diseases. A short-term controlled study. Med Praxis 1984;5:147-152.
38. Eftimiadi C, DeLeo C, Schito GC: Treatment of hepatic encephalopathy with L/105, a new non-absorbable rifamycin. Drugs Exp Clin Res 1984;10:691-696.
39. Gruttaduria G, LaBarbera F, Cutaia G, Salanitri G: Prevention of infection in colonic surgery by rifaximin. A controlled prospective randomized trial. Eur Rev Med Pharmacol Sci 1987;9:101-105.
40. Papi C, Ciacco A, Koch M, Capurso L: Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Diverticular Disease Study Group. Ital J Gastroenterol 1992;24:452-456.
41. Corazza GR, Ventrucci M, Strocchi A, Sorge M, Pranzo L, Pezzilli R, Gasbarrini G: Treatment of small intestine bacterial overgrowth with rifaximin, a non-absorbable rifamycin. J Int Med Res 1988;16:312-316.
42. Di Stefano M, Malservisi S, Veneto G, Ferrieri A, Corazza GR: Rifaximin versus chlortetracycline in the short-term treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther 2000;14:551-556.
43. Trespi E, Ferrieri A: Intestinal bacterial overgrowth during chronic pancreatitis. Curr Med Res Opin 1999,15:47-52.
44. Di Stefano M, Strocchi A, Malservisi S, Veneto G, Ferrieri A, Corazza GR: Non-absorbable antibiotics for managing intestinal production and gas-related symptoms. Aliment Pharmacol Ther 2000;14:1001-1008.
45. Attar A, Flourie B, Rambaud JC, Franchisseur C, Ruszniewski P, Bouhnik Y: Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: A crossover, randomized trial. Gastroenterology 1999;117:794-797.
46. Di Stefano M, Pezzimenti D, Veneto G, Missanelli A, Corazza GR: Absorbable vs. non-absorbable antibiotics in the therapy of small intestine bacterial overgrowth (SIBO) in patients with blind loop syndrome. Dig Liver Dis 2001;33:A93.